4th Annual CKD Drug Development Summit

Published on 01/03/2022

1-3 March, 2022
Boston, USA

ENYO attended the 4th Chronic Kidney Disease Drug Development Summit, the only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. We presented a poster entitled “VONAFEXOR induces renal and hepatic improvements in NASH-LIVIFY trial results”.

https://ckd3-summit.com/

Read next in 'Events'

• The 2024 international workshop on Alport syndrome
• ENYO Pharma annonce un financement de Série C de 39 millions d'euros et l’autorisation de la FDA (IND) pour tester Vonafexor dans un essai clinique de Phase 2 pour les patients atteints du syndrome d'Alport
• 6th CKD Summit – Chronic Kidney Disease Drug Development
• ASN Kidney Week
• Alport Connect 2023, the annual Alport syndrome patient and family meeting in US